Menu Search
Equities

Navamedic ASA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
N1A:FRA

Navamedic ASA

Actions
  • Price (EUR)1.90
  • Today's Change0.015 / 0.80%
  • Shares traded150.00
  • 1 Year change-9.53%
  • Beta0.2423
Data delayed at least 15 minutes, as of Feb 06 2026 20:47 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Navamedic ASA is a Norway-based pharmaceutical company. It is a supplier of products delivered to hospitals and pharmacies. Navamedic’s product portfolio consists of prescription and Over The Counter (OTC) pharmaceuticals as well as other healthcare products registered as medical nutrition, medical devices, food supplements or cosmetics. The Company’s offering is divided into four product areas: Consumer Health, Specialty Pharma, Medical Nutrition and Branded Generics. The Company has one business segment which is the Pharma division. Navamedic ASA is present in all Nordic countries, the Baltics and Benelux. The Company has two subsidiaries, Navamedic AB, through which the Company distributes more than 40 products and a Norway-based Novicus Pharma AS.

  • Revenue in NOK (TTM)539.42m
  • Net income in NOK-39.43m
  • Incorporated2002
  • Employees45.00
  • Location
    Navamedic ASAHenrik Ibsens gate 100OSLO 0255NorwayNOR
  • Phone+47 67112540
  • Fax+47 67112541
  • Websitehttps://navamedic.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		NAVA:OSL since
announced		Transaction
value
Dne Pharma ASDeal completed23 Jun 202523 Jun 2025Deal completed7.02%22.34m
Data delayed at least 15 minutes, as of Feb 06 2026.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.